Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore's lead T-cell receptor based investigational therapeutic, for the potential treatment of patients with metastatic melanoma.
MedImmune has an exclusive relationship with Immunocore for the development of IMCgp100 in combination with MEDI4736 and/or tremelimumab, and will have first right of negotiation for the future commercial development of these combinations for tumours expressing gp100.
|Searching for more deal information? Current Partnering offers the following options:|
Immunocore and MedImmune will collaborate to establish a dosing regimen for IMCgp100 combined with MEDI4736 and/or tremelimumab, as part of the Phase Ib study.
The Phase II study will assess the safety and efficacy of the different combinations.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies